Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance

Breast cancer is one of the most common cancer and leading causes of death in women in the United States and Worldwide. About 90% of breast cancers belong to ER+ or HER2+ subtypes and are driven by key breast cancer genes Estrogen Receptor and HER2, respectively. Despite the advances in anti-estroge...

Descripción completa

Detalles Bibliográficos
Autores principales: Bick, Gregory, Zhang, Jasmine, Lower, Elyse E., Zhang, Xiaoting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255246/
https://www.ncbi.nlm.nih.gov/pubmed/35800368
http://dx.doi.org/10.20517/cdr.2022.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255246/
https://www.ncbi.nlm.nih.gov/pubmed/35800368
http://dx.doi.org/10.20517/cdr.2022.33

Ejemplares similares